Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.

NCT02977195 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT02977195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02977195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
Lead sponsor
Centre Leon Berard
Phase
Phase 1
Overall status
Completed
Start date
January 9, 2017
Completion date
June 30, 2022
Enrollment
70 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, endometrial carcinoma, hormone receptor positive